rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2011-1465rsp-1297Research ArticleСтатьиArticlesГОМОЗИГОТНАЯ МУТАЦИЯ В ГЕНЕ ИНГИБИТОРА АКТИВАТОРА ПЛАЗМИНОГЕНА 1 У ПАЦИЕНТОВ С АНТИФОСФОЛИПИДНЫМ СИНДРОМОМGOMOZIGOTNAYa MUTATsIYa V GENE INGIBITORA AKTIVATORA PLAZMINOGENA 1 U PATsIENTOV S ANTIFOSFOLIPIDNYM SINDROMOMОстряковаЕ. В.OstryakovaE. V.ПатрушеваН. Л.PatrushevaN. L.АлексанкинА. П.AleksankinA. P.ПатрушевЛ. И.PatrushevL. I.СередавкинаН. В.SeredavkinaN. V.АлександроваЕлена НиколаевнаAleksandrovaE. N.ВолковА. В.VolkovA. V.РешетнякТ. М.ReshetnyakT. M.katerina.ostryakova@yandex.rukaterina.ostryakova@yandex.ru201115062011495№5 (2011)8388Copyright © Острякова Е.В., Патрушева Н.Л., Алексанкин А.П., Патрушев Л.И., Середавкина Н.В., Александрова Е.Н., Волков А.В., Решетняк Т.М., 20112011Острякова Е.В., Патрушева Н.Л., Алексанкин А.П., Патрушев Л.И., Середавкина Н.В., Александрова Е.Н., Волков А.В., Решетняк Т.М.Ostryakova E.V., Patrusheva N.L., Aleksankin A.P., Patrushev L.I., Seredavkina N.V., Aleksandrova E.N., Volkov A.V., Reshetnyak T.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/1297

Антифосфолипидный синдром (АФС) – симптомо- комплекс, проявляющийся тромбозом сосудов различной локализации и калибра при обязательном наличии в крови антифосфолипидных антител (аФЛ) [1]. К серологическим маркерам АФС, согласно международным диагностическим критериям, отнесены: антитела к кардиолипину (аКЛ) и/или волчаночный антикоагулянт (ВА), и/или антитела к β2-гликопротеину 1 (анти-β2-ГП 1). В зависимости от позитивности по аФЛ рекомендовано стратифицировать больных АФС по следующим категориям: I – выявление более одного лабораторного маркера (в любой комбинации); IIа – только ВА; IIb – только аКЛ; IIc – только анти-β2-ГП 1 [2] 

Antifosfolipidnyi sindrom (AFS) – simptomo- kompleks, proyavlyayushchiisya trombozom sosudov razlichnoi lokalizatsii i kalibra pri obyazatel'nom nalichii v krovi antifosfolipidnykh antitel (aFL) [1]. K serologicheskim markeram AFS, soglasno mezhdunarodnym diagnosticheskim kriteriyam, otneseny: antitela k kardiolipinu (aKL) i/ili volchanochnyi antikoagulyant (VA), i/ili antitela k β2-glikoproteinu 1 (anti-β2-GP 1). V zavisimosti ot pozitivnosti po aFL rekomendovano stratifitsirovat' bol'nykh AFS po sleduyushchim kategoriyam: I – vyyavlenie bolee odnogo laboratornogo markera (v lyuboi kombinatsii); IIa – tol'ko VA; IIb – tol'ko aKL; IIc – tol'ko anti-β2-GP 1 [2]

References<div><p>Антифосфолипидный синдром. Под ред. Е.Л. Насонова. М.: Литтерра, 2004;434 с.</p><p>Антифосфолипидный синдром. Под ред. Е.Л. Насонова. М.: Литтерра, 2004;434 с.</p><p>Myakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006;4:295-306.</p><p>Angles-Cano E. Endothelial damage and hypofibrinolysis in systemic lupus erythematosus. J Thromb Haemost 1989;61(2):322</p><p>Glas-Greenwalt P., Kant K.S., Allen C., Pollak V.E. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. J Lab Clin Med 1984;104(6):962-76</p><p>Awada H., Barlowatz-Meimor G., Dougados M. et al. Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis. J Lab Clin Med 1988;111(2):229-36</p><p>Инфекционные болезни. Под ред. С.Г. Пак. М.: МИА, 2008;87-93.</p><p>Giannakopoulos B., Passam F., Rahgozar S., Krilis S.A. Current concepts on the pathogenesis of the antiphospholipid syndrome. J Blood 2007;109:422-30</p><p>Vega-Ostertag M., Pierangeli S.S. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. J Curr Rheumatol Rep 2007;9:190-7</p><p>Pierangeli S.S., Chen P.P., Gonzalez E.B. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. J Curr Opin Hematol 2006;13:366-75</p><p>Koike T., Bohgaki M., Amengual O., Atsumi T. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 2007;28:129-33.</p><p>Harpel P.C., Chang T.S., Verdeber E. Tissue plasminogen activator and urocinase mediates the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin. J Biol Chem 1985;260:4432-40</p><p>Fleury V., Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfase: the role of carboxy-terminal lyses. J Biochemestry 1991;30:7630-8</p><p>Nilsson I.M., Tengborn L. Impaired fibrinolysis: new evidence in relation to thrombosis. J Press (pub.), 1983;273-91</p><p>Sobel B.E., Woodcock-Mitchell J., Schneider D.J. et al. Increased plasminogenactivator inhibitor type 1 in coronary artery atherectomy speciment from type 2 diabetic compared with nondiabetic patients. J Circulation 1998;97:2213-21</p><p>Kaitita K., Schoenhard J.A., Painter C.A. et al. Potential roles of plasminogen-activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibitor. J Mol Cell Cardio 2002;34:617-27</p><p>Forastiero R., Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. J Lupus 2008;17:872-7.</p><p>Forastiero R., Martinuzzo M. Antigen specificity and clinical relevance of antiphospholipid syndrome-related autoantibodies. J Curr Rheumatol Rev 2005;1:177-87</p><p>Tassies D., Espinosa G., Munoz-Rodriguez F. et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthr Rheum 2000;43:2349-58</p><p>Forastiero R., Martinuzzo M., Adamczuk Y. et al. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. J Haematologica 2001;86:735-41.</p><p>Yasuda S., Tsutsumi A., Atsumi T. et al. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 2002;29:1192-7.</p><p>Wang A.Y.M., Poon P., Lai F. et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. J Kidney International 2001;59:1520-8.</p><p>Кондратьева Л.В., Патрушева Н.Л., Патрушев Л.И. Рецидивы тромбозов и геморрагических осложнений у больных с антифосфолипидным синдромом на фоне терапии варфарином. Тер арх 2010;5:33-9</p><p>Joffe H.V., Xu R., Johnson F.B. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. J Thromb Haemost 2004;91:1123-8.</p><p>Gage B.F., Lesko L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolys 2008;25:45-51</p></div><br /><div><p>Антифосфолипидный синдром. Под ред. Е.Л. Насонова. М.: Литтерра, 2004;434 с.</p><p>Антифосфолипидный синдром. Под ред. Е.Л. Насонова. М.: Литтерра, 2004;434 с.</p><p>Myakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006;4:295-306.</p><p>Angles-Cano E. Endothelial damage and hypofibrinolysis in systemic lupus erythematosus. J Thromb Haemost 1989;61(2):322</p><p>Glas-Greenwalt P., Kant K.S., Allen C., Pollak V.E. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. J Lab Clin Med 1984;104(6):962-76</p><p>Awada H., Barlowatz-Meimor G., Dougados M. et al. Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis. J Lab Clin Med 1988;111(2):229-36</p><p>Инфекционные болезни. Под ред. С.Г. Пак. М.: МИА, 2008;87-93.</p><p>Giannakopoulos B., Passam F., Rahgozar S., Krilis S.A. Current concepts on the pathogenesis of the antiphospholipid syndrome. J Blood 2007;109:422-30</p><p>Vega-Ostertag M., Pierangeli S.S. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. J Curr Rheumatol Rep 2007;9:190-7</p><p>Pierangeli S.S., Chen P.P., Gonzalez E.B. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. J Curr Opin Hematol 2006;13:366-75</p><p>Koike T., Bohgaki M., Amengual O., Atsumi T. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 2007;28:129-33.</p><p>Harpel P.C., Chang T.S., Verdeber E. Tissue plasminogen activator and urocinase mediates the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin. J Biol Chem 1985;260:4432-40</p><p>Fleury V., Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfase: the role of carboxy-terminal lyses. J Biochemestry 1991;30:7630-8</p><p>Nilsson I.M., Tengborn L. Impaired fibrinolysis: new evidence in relation to thrombosis. J Press (pub.), 1983;273-91</p><p>Sobel B.E., Woodcock-Mitchell J., Schneider D.J. et al. Increased plasminogenactivator inhibitor type 1 in coronary artery atherectomy speciment from type 2 diabetic compared with nondiabetic patients. J Circulation 1998;97:2213-21</p><p>Kaitita K., Schoenhard J.A., Painter C.A. et al. Potential roles of plasminogen-activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibitor. J Mol Cell Cardio 2002;34:617-27</p><p>Forastiero R., Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. J Lupus 2008;17:872-7.</p><p>Forastiero R., Martinuzzo M. Antigen specificity and clinical relevance of antiphospholipid syndrome-related autoantibodies. J Curr Rheumatol Rev 2005;1:177-87</p><p>Tassies D., Espinosa G., Munoz-Rodriguez F. et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthr Rheum 2000;43:2349-58</p><p>Forastiero R., Martinuzzo M., Adamczuk Y. et al. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. J Haematologica 2001;86:735-41.</p><p>Yasuda S., Tsutsumi A., Atsumi T. et al. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 2002;29:1192-7.</p><p>Wang A.Y.M., Poon P., Lai F. et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. J Kidney International 2001;59:1520-8.</p><p>Кондратьева Л.В., Патрушева Н.Л., Патрушев Л.И. Рецидивы тромбозов и геморрагических осложнений у больных с антифосфолипидным синдромом на фоне терапии варфарином. Тер арх 2010;5:33-9</p><p>Joffe H.V., Xu R., Johnson F.B. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. J Thromb Haemost 2004;91:1123-8.</p><p>Gage B.F., Lesko L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolys 2008;25:45-51</p></div><br />

The authors declare that there are no conflicts of interest present.